Strategic Investment Solutions Inc. IL Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

Strategic Investment Solutions Inc. IL lessened its holdings in Pfizer Inc. (NYSE:PFE) by 35.8% during the first quarter, Holdings Channel.com reports. The firm owned 4,300 shares of the biopharmaceutical company’s stock after selling 2,399 shares during the quarter. Strategic Investment Solutions Inc. IL’s holdings in Pfizer were worth $109,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. Bank of America lifted their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Wolfe Research lifted their price objective on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group lifted their price objective on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.28.

Pfizer Trading Up 0.9%

PFE stock opened at $23.49 on Monday. The company has a market cap of $133.55 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 0.85 and a beta of 0.52. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The business has a fifty day simple moving average of $24.36 and a 200-day simple moving average of $24.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.32.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.